Citation Impact
Citing Papers
A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema
2007
Ranibizumab for the Treatment of Macular Edema Associated with Perfused Central Retinal Vein Occlusions
2008
A SYSTEMATIC REVIEW OF THE ADVERSE EVENTS OF INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS
2011
Diabetic retinopathy
2010 Standout
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
2015 Standout
Prevalence and Control of Diabetes in Chinese Adults
2013 Standout
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature
2013 Standout
Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: A 3-Year Multicenter, Randomized, Controlled Clinical Trial
2011
One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema
2012
Regulation of retinal blood flow in health and disease
2008
Management of Diabetic Retinopathy
2007
Intravitreal Ranibizumab May Induce Retinal Arteriolar Vasoconstriction in Patients with Neovascular Age-related Macular Degeneration
2009
Diabetic Retinopathy
2012 Standout
Diabetic retinopathy and systemic vascular complications
2007
Microvascular Modifications in Diabetic Retinopathy
2011
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
CLINICAL CHARACTERISTICS OF ENDOPHTHALMITIS AFTER AN INJECTION OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR
2010
A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study)
2010
INTRAVITREAL BEVACIZUMAB PLUS GRID LASER PHOTOCOAGULATION OR INTRAVITREAL BEVACIZUMAB OR GRID LASER PHOTOCOAGULATION FOR DIFFUSE DIABETIC MACULAR EDEMA
2012
Emerging drugs for diabetic retinopathy
2008
Ranibizumab for Diabetic Macular Edema
2012 Standout
Etiology and Treatment of Macular Edema
2008
Ranibizumab for Macular Edema following Central Retinal Vein Occlusion
2010 Standout
Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease
2011
Intravitreal Triamcinolone Acetonide Injection for Treatment of Refractory Diabetic Macular Edema
2009
Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up
2009
Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy
2015 StandoutNobel
Expression Pattern of HIF-1α and VEGF Supports Circumferential Application of Scatter Laser for Proliferative Sickle Retinopathy
2016 StandoutNobel
VEGF Secreted by Hypoxic Müller Cells Induces MMP-2 Expression and Activity in Endothelial Cells to Promote Retinal Neovascularization in Proliferative Diabetic Retinopathy
2013 StandoutNobel
A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Focal/Grid Photocoagulation for Diabetic Macular Edema
2008
Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy
2013
Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture
2011
Works of Dal Chun being referenced
A Pilot Study of Multiple Intravitreal Injections of Ranibizumab in Patients with Center-Involving Clinically Significant Diabetic Macular Edema
2006